Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 2/5/18

|Includes: EIGR, Kadmon Holdings, Inc. (KDMN)
Summary

This week transcripts discuss: KDMN, 2 calls on EIGR.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: KDMN

Investigating Kadmon's ROCK Inhibitor Platform In Fibrosis, Specifically KD025 In IPF

Call Date: 1/05/18 at 11:00am ET.

Who's the Expert? Institution: University of Chicago

  • Medical Director, Heart & Vascular Center University of Chicago Medical Center.
  • Co-Author of the paper: "The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis".
  • Currently treats 12 Idiopathic Pulmonary Fibrosis patients and has a research focus on Rock2 Inhibition.

Link to original project page on Slingshot Insights with questions asked: Link

Transcript 2: EIGR

Discussing Eiger Biopharma's Ubenimex In Treating Pulmonary Arterial Hypertension Ahead Of Phase 2 Data

Call Date: 1/05/18 at 9:00am ET.

Who's the Expert? Institution: Duke University

  • Cardiologist & Assistant Professor of Medicine at Duke University School of Medicine.

  • Treats 100 patients with pulmonary arterial hypertension.

  • Active in basic science research and is site PI on the LIBERTY trial for ubenimex.

Link to original project page on Slingshot Insights with questions asked: Link

Transcript 3: EIGR

Another Opinion: Discussing Eiger Biopharma's Ubenimex In Treating Pulmonary Arterial Hypertension Ahead Of Phase 2 Data

Call Date: 1/05/18 at 12:00pm ET.

Who's the Expert? Institution: Stanford University 

  • Chief of Pulmonary and Critical Care Medicine at Stanford.
  • Senior author of study behind LIBERTY Trial and leader of first NIH Multicenter trial of immunotherapy for PAH.
  • Group designed ubinimex as a treatment for PAH and published findings in Science Translational Medicine.

Link to original project page on Slingshot Insights with questions asked: Link